Roundtable Prostate Cancer
Panel experts discuss PSMA-targeting agents currently being assessed, including PSMA-I&T-Lutetium-177.
Dr. Oliver Sartor and Dr. Rana McKay discuss some limitations (and advantages) of lutetium-177-PSMA.
Dr. Oliver Sartor weighs in on lutetium-177-PSMA as an effective therapy for prostate cancer.
The palliative benefits of lutetium-177 PSMA are discussed, including reduced symptom burden compared with standard of care.
Drs. George and Sprenkle discuss PSMA PET scans, including challenges and the potential of Lutetium-based PSMA treatments.
The panel discusses lutetium-177-PSMA for the treatment of advanced prostate cancer and reviews the VISION trial.
Drs. Agarwal, Calais, and Tward discuss the use of radiopharmaceutical-based therapeutics in patients with prostate cancer.
Drs. Agarwal and Tagawa discuss the VISION trial and how lutetium-177 PSMA-617 will be used to treat metastatic CRPC.
Drs. Agarwal and Tagawa discuss PSMA imaging and the future of CT scans in the follow-up of metastatic prostate cancer.
Drs. Agarwal and Tward discuss the use of PSMA imaging for oncologists and urologists dealing with localized prostate cancer.
Drs. Agarwal and Calais review the basics of PSMA imaging of prostate cancer and what makes it unique.
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.